Over the past 18 months, the COVID-19 pandemic has brought the treatment and prevention of infectious diseases to center stage. For Dr. Adeeba Kamarulzaman, Dean of the Faculty of Medicine at University of Malaya in Kuala Lumpur, Malaysia, and Dr. Sharon Lewin, Professor of Medicine at the University of Melbourne in Melbourne, Australia, the pandemic offers an opportunity for the global health community to review its approach to HIV prevention and treatment and to plot a stronger course going forward.
When Wayne Duffus moved from Jamaica to New York after high school, he quickly developed an interest in science thanks to a handful of inspiring mentors. His family was immigrating to the United States, and he was excited to attend City University of New York – Brooklyn College. After graduation, as he continued exploring his newly found passion, he enrolled in an MD-PhD program at the Albert Einstein College of Medicine and eventually went on to specialize in infectious diseases to help fight the growing HIV epidemic. Since then, he has focused his work on HIV prevention in the clinical, public health and government sectors.
At Gilead, we are dedicated to looking beyond the obvious to solve complex problems. Read more about our efforts to rise beyond in 2020 as we worked amid the pandemic to deliver for patients.
Gilead Sciences to Acquire Immunomedics
An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences
People who are most vulnerable to #HIV, including transgender women, often face difficult barriers to accessing prevention and care, including stigma and discrimination. Help replace stigma with science by spreading facts about HIV. Watch this video with Blossom from the Los Angeles LGBT Center and talk to a healthcare provider for more information on your sexual health: http://glassdoor.com/slink.htm?key=vM4lX. #SpreadFactsNotFear
The increasing availability of effective #HIV treatments within low and middle-income countries has produced encouraging signs of progress, yet there is more work to be done to fight the epidemic. Our VP of Access Operations and Emerging Markets, Papa Salif Sow, expands on this global-scale effort to improve access in this month’s issue of New Scientist: http://glassdoor.com/slink.htm?key=vQwXY.
People living with HIV can now live longer, fuller lives thanks to a series of biomedical breakthroughs and the dedication of thousands of researchers around the world. Learn more about 30 years of progress in HIV treatment from our Medical Director, Peter Borg, in the most recent issue of New Scientist: http://glassdoor.com/slink.htm?key=vQNTY.
More than 12,000 people in Alabama were living with HIV in 2014. Douglas Brooks, our Senior Director for Community Engagement, and Nic Carlisle of the Southern AIDS Coalition highlight a new partnership with the Southern HIV/AIDS Strategy Initiative at Duke University as part of the Gilead COMPASS Initiative™ Corporate Giving Program which aims to combat the HIV/AIDS epidemic in Birmingham, AL and across the Southern U.S. Read more at http://glassdoor.com/slink.htm?key=vQsIV: http://glassdoor.com/slink.htm?key=vQsIz.
We at Gilead Sciences support our colleagues at Kite Pharma and their dedication to driving cancer research that has the potential to improve the lives of people living with the disease around the world. #WorldCancerDay